Daily Cardiology Research Analysis
Analyzed 261 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stand out today: a mechanistic European Heart Journal study uncovers how endurance exercise remodels pulmonary vein sleeves to create both triggers and substrate for atrial fibrillation; a prespecified analysis from the VESALIUS-CV randomized trial in Circulation clarifies that Lp(a) independently predicts major coronary events and that evolocumab reduces risk irrespective of baseline Lp(a); and a nationwide Korean cohort in European Heart Journal links lifetime hormonal exposure to lower heart failure risk and mortality after heart failure.
Research Themes
- Mechanistic pathways linking endurance exercise to atrial fibrillation substrate and triggers
- Risk stratification by Lp(a) and lipid-lowering therapy effects in primary prevention populations
- Sex-specific and hormonal determinants of heart failure risk and outcomes
Selected Articles
1. Endurance exercise remodels pulmonary vein sleeve myocytes and promotes a proarrhythmic atrial substrate.
Using endurance training models across species with spatial transcriptomics and in silico validation, this study shows that exercise upregulates automaticity (HCN4/Ca2+ channels), slows conduction (SCN5A/Cx43), and promotes fibrosis/inflammation in pulmonary vein sleeves, leading to enhanced PV firing and peri-antral reentry. The findings mechanistically explain why PV isolation benefits athlete AF and nominate modifiable pathways (e.g., HCN4, TNFα).
Impact: It provides a rigorous, multi-system mechanistic map linking endurance exercise to AF triggers and substrate at the PV–LA junction, integrating omics and electrophysiology with human modeling.
Clinical Implications: Supports PV-focused ablation in athlete AF and suggests adjunct strategies targeting automaticity (HCN4/Ca channels) and inflammation/fibrosis (e.g., TNFα pathways) to prevent recurrence.
Key Findings
- Endurance training increased AF inducibility with PV–LA conduction slowing and rotational activity in vivo.
- PV sleeves showed enhanced β-adrenergic–evoked firing, prolonged bursts, and more pacemaker-like action potentials ex vivo.
- Spatial transcriptomics revealed upregulation of Hcn4/Cacna1d/Cacna1g and downregulation of Scn5a/Gja1, alongside fibroblast expansion and pro-fibrotic/inflammatory signaling (TNFα, IL-6).
- In silico human models reproduced faster spontaneous PV firing and sustained peri-antral reentry from observed molecular and electrophysiologic changes.
Methodological Strengths
- Multi-modal integration: in vivo mapping, ex vivo electrophysiology, histology, bulk and spatial transcriptomics, and in silico human modeling
- Cross-species endurance models enhancing generalizability and mechanistic validation
Limitations
- Preclinical models may not capture all human athletic phenotypes and environmental modifiers
- Causal interventional testing of nominated pathways (e.g., HCN4/TNFα) was not performed in vivo
Future Directions: Interventional studies targeting HCN4/Ca-channel automaticity and TNFα/inflammatory signaling in exercise-induced AF models; prospective biomarker-guided human studies to translate pathway targets to prevention or adjunctive therapy.
BACKGROUND AND AIMS: The risk of atrial fibrillation (AF) is higher in endurance athletes. Pulmonary vein isolation (PVI) is effective in this group, implicating pulmonary vein (PV) remodelling, but underlying mechanisms are unclear. This study investigated if endurance training remodels PV sleeves and the PV-left atrial (LA) junction to promote PV triggers and a permissive peri-antral substrate for AF. METHODS: In canine and murine endurance-running models, in vivo PV-LA mapping, ex vivo PV electrophysiology, intracellular action potential (AP) profiling with machine learning classification, histology, bulk RNA-seq, and subcellular-resolution spatial transcriptomics of PV-LA tissue were performed. These findings were incorporated into biophysically detailed computer models of human PV cardiomyocytes and a 3D human LA. RESULTS: Training produced an athlete's heart phenotype and increased AF inducibility. In vivo, trained animals showed PV-LA conduction slowing and increased rotational activity. Ex vivo, trained PVs showed enhanced β-adrenergically evoked firing, prolonged burst activity, and a higher proportion of pacemaker-like APs. Spatial transcriptomics revealed discrete PV myocyte subpopulations with training upregulated Hcn4, Cacna1d, and Cacna1g (enhancing automaticity), downregulated Scn5a and Gja1 (slowing conduction), and enriched profibrotic/inflammatory signalling (Tnfα, Il6) alongside fibroblast expansion and extracellular matrix deposition. In silico, these changes reproduced faster spontaneous PV firing and sustained re-entry. CONCLUSIONS: Endurance training drives coupled electrical, structural, and inflammatory PV-LA remodelling that provides both trigger and substrate for AF. These data support why PV-targeted strategies can be effective in athletic AF and nominate modifiable pathways including HCN4-linked automaticity and TNFα-associated signalling.
2. Lipoprotein(a) Levels, Risk of Cardiovascular Events and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.
In this prespecified analysis of the VESALIUS-CV randomized trial (n=7,557), baseline Lp(a) independently predicted major coronary events in high-risk patients without prior MI or stroke, while evolocumab reduced relative risk similarly across Lp(a) strata. Absolute risk reduction tended to be greater at higher Lp(a), supporting Lp(a)-guided risk communication and therapy prioritization.
Impact: Clarifies the prognostic role of Lp(a) and informs how PCSK9 inhibition delivers benefit across Lp(a) levels in a primary prevention-like population with established risk.
Clinical Implications: Measure Lp(a) to refine risk stratification and communicate absolute benefit; evolocumab use can be justified irrespective of Lp(a), with potentially greater absolute gains when Lp(a) is elevated.
Key Findings
- Baseline Lp(a) independently associated with higher risk of major coronary events in placebo-treated patients.
- Evolocumab reduced relative risk of major coronary events regardless of baseline Lp(a) concentration.
- Numerically greater absolute risk reduction with evolocumab in patients with elevated Lp(a), supporting pragmatic risk–benefit communication.
Methodological Strengths
- Prespecified analysis within a large, randomized, placebo-controlled outcomes trial
- Robust time-to-event modeling across Lp(a) strata with clinically relevant composite endpoints
Limitations
- Subgroup/prespecified analysis may be underpowered for interaction testing with ischemic stroke
- Generalizability limited to high-risk patients without prior MI or stroke enrolled in the trial
Future Directions: Evaluate absolute benefit thresholds integrating Lp(a) with global risk and apoB to guide therapy intensity; test combined Lp(a)-lowering agents plus PCSK9 inhibition in high Lp(a) phenotypes.
BACKGROUND: Lipoprotein(a) [Lp(a)] is a risk factor for coronary heart disease. Whether baseline Lp(a) identifies higher risk patients who derive more benefit from evolocumab is not established in a population without prior myocardial infarction (MI) or stroke. METHODS: From June 2019 to November 2021, the VESALIUS-CV trial enrolled patients with qualifying atherosclerosis or high-risk diabetes, without prior MI or stroke and randomized them to evolocumab or placebo (median follow-up 4.6 years). In a prespecified analysis, Lp(a) was assessed at baseline in 7557 patients. Cox models were used to assess the adjusted risk of cardiovascular events by baseline Lp(a) in the placebo arm, and the efficacy of evolocumab by baseline Lp(a). The primary outcome of interest was the composite of major coronary events (coronary heart disease death, MI or urgent coronary revascularization). RESULTS: Median age was 66 [interquartile range 60-71] years and 42.8% were women; median Lp(a) was 28 (interquartile range 9-132) nmol/L. Higher baseline Lp(a) was associated with an increased risk of major coronary events (HR CONCLUSIONS: In patients with atherosclerosis or high-risk diabetes but without prior MI or stroke, Lp(a) was independently associated with an increased risk of major coronary events, but not ischemic stroke. Evolocumab reduced the relative risk of major coronary events to a similar degree irrespective of baseline Lp(a), with a numerically greater absolute risk reduction in patients with elevated Lp(a).
3. Reproductive history, hormonal exposure, and risk of heart failure in postmenopausal women: a Korean nationwide study.
In over 3.6 million postmenopausal women followed for a median 10 years, longer reproductive exposure (later menopause, longer reproductive period) and exogenous hormone use (OC, MHT) were associated with lower incident HF and reduced mortality after HF. Earlier menarche, earlier menopause, and shorter reproductive period conferred higher HF risk and mortality.
Impact: Establishes sex-specific, hormonally linked determinants of heart failure risk and outcomes using nationwide data with competing risk methods.
Clinical Implications: Incorporate reproductive history and hormonal exposure into HF risk assessment for women; findings support nuanced counseling about timing of menopause and potential cardiovascular implications of OC/MHT use.
Key Findings
- Oral contraceptive (≥1 year) and menopausal hormone therapy (≥5 years) use were associated with lower incident HF.
- Later menarche, earlier menopause, and shorter total reproductive period were linked to higher HF risk.
- Among women hospitalized for HF, OC and MHT use were associated with lower mortality, whereas earlier menarche/menopause and shorter reproductive period were associated with higher mortality.
Methodological Strengths
- Very large nationwide cohort with robust statistical power and Fine-Gray competing risk models
- Comprehensive evaluation of endogenous and exogenous hormonal exposures with long follow-up
Limitations
- Observational design limits causal inference and residual confounding is possible
- Exposure misclassification and lack of granular hormone formulations/dosing cannot be excluded
Future Directions: Mechanistic studies on hormonal modulation of myocardial structure/function in women; prospective trials to clarify cardiovascular safety signals and optimize timing/duration of MHT.
BACKGROUND AND AIMS: Evidence on the association between female-specific factors and heart failure (HF) remains limited. This study examined their associations with HF and subsequent mortality. METHODS: Using the Korean National Health Insurance Service database, 3 692 157 postmenopausal women without prior HF or structural heart disease and with intact ovaries and uterus were identified. Associations between reproductive factors, including parity, breastfeeding duration, oral contraceptive (OC) and menopausal hormone therapy (MHT) use, age at menarche, age at menopause, and total reproductive period, and HF risk were assessed using Fine-Gray competing risk models, with death treated as a competing event. Among women with HF hospitalization, associations between reproductive factors and mortality were evaluated using multivariable Cox regression. RESULTS: During a median follow-up of 120 months, 48 640 women were hospitalized for HF. OC (sub-distribution hazard ratios [SHRs]≥1y vs non-user: 0.942, 99.3% confidence interval [CI] 0.896-0.990) or MHT (SHR≥5y vs non-user: 0.782 [99.3% CI 0.708-0.863]) use was associated with a lower HF risk. Later menarche (SHRage≥17 vs 13-16y: 1.099 [99.3% CI 1.071-1.128]), earlier menopause (SHRage 40-44y vs 50-54y: 1.229 [99.3% CI 1.173-1.288]), and shorter reproductive period (SHRage <30y vs ≥40y: 1.284 [99.3% CI 1.213-1.361]) were linked to higher HF risk (all P for trend <.001). Among women with HF, OC, and MHT use were associated with lower mortality, while earlier menarche, earlier menopause, and shorter reproductive period were linked to increased mortality. CONCLUSIONS: Prolonged lifetime exposure to both endogenous and exogenous female sex hormones is associated with lower HF incidence and subsequent mortality.